Grading and Staging MCQ — NEET PG Practice Question | NEETPGAI
Grading and Staging
medium
microscope Pathology
A 65-year-old man from Bangalore presents with hematuria and is found to have a 5 cm mass in the left kidney on contrast-enhanced CT. There is no evidence of renal vein invasion, and staging CT chest/abdomen shows no distant metastases. Biopsy confirms clear cell renal cell carcinoma (RCC), Fuhrman grade 3. What is the most appropriate next step in management?
A. Percutaneous renal artery embolization followed by observation
B. Systemic targeted therapy (sunitinib or sorafenib) without surgery
C. Radical nephrectomy with regional lymph node dissection
D. Partial nephrectomy (nephron-sparing surgery)
Explanation
Management of Localized Renal Cell Carcinoma
Key Point
For localized RCC without distant metastases, surgical resection is the only curative approach. The choice between radical and partial nephrectomy depends on tumor size, grade, and renal function.
Why Radical Nephrectomy Is Indicated
High-YieldNEET PG
This patient has:
T2, N0, M0 disease (stage III by AJCC)
5 cm tumor (exceeds the 4 cm threshold for nephron-sparing surgery)
Fuhrman grade 3 (high-grade, aggressive)
No renal vein invasion
Indications for Radical Nephrectomy:
Table
Feature
Radical Nephrectomy
Partial Nephrectomy
Tumor size
>4 cm
≤4 cm (or select T1b)
Grade
High-grade (3–4)
Low-grade (1–2)
Renal function
Normal or one kidney
Solitary kidney, CKD
Vascular invasion
Present
Absent
Margin adequacy
Easier to achieve
Requires careful dissection
Clinical Pearl
Partial nephrectomy is preferred for T1a (≤4 cm) tumors to preserve renal function, but this patient's 5 cm, grade 3 tumor is best managed with radical nephrectomy to ensure adequate oncologic margins and regional lymph node assessment.
Treatment Algorithm for Localized RCC
Loading diagram...
Mnemonic
GRADE-RCC = Great tumor (>4 cm) → Radical nephrectomy; Adenocarcinoma grade 3–4 → Define margins; Early stage, small → Renal-sparing; Clear cell type → Curative surgery first.
Warning
Systemic therapy (sunitinib, sorafenib) is reserved for metastatic or unresectable disease. It is not a substitute for surgery in localized disease.
Robbins 10e Ch 18
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.